Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q3 2024 · 10-Q
Revenue$9.02M$9.02M−42.1% vs Q3 2023 Net Income$169.38M$169.38M−96.7% vs Q3 2023 EPS Diluted$0.23$0.23−96.2% vs Q3 2023 Operating Income-$274,381,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$209,078,000N/M Margins · derivedOperating margin-3042.6%
Net margin1878.3%
ended Dec 31, 2024 · filed Feb 10, 2025 · 41 d after period end